INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...

Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...

A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as ...

A NEW method for detecting bowel cancer is more than 90 per cent accurate at predicting which higher risk people will develop ...

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...